This week in therapeutics

Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Endocrine/metabolic disease

Metabolic disease

G protein-coupled receptor 171 (GPR171)

Cell culture and mouse studies suggest modulating GPR171 activity could help treat metabolic disorders. In cultured neurons, a peptide previously shown to regulate body weight called BigLEN was shown to bind and activate GPR171. In mice, small hairpin RNA knockdown of Gpr171 combined with intracerebroventricular injection of an anti-BigLEN antibody decreased food intake compared with no knockdown. Next steps include screening for agonists and antagonists of GPR171.

SciBX 6(41); doi:10.1038/scibx.2013.1162
Published online Oct. 24, 2013

Unpatented; licensing status not applicable

Gomes, I. et al. Proc. Natl. Acad. Sci. USA; published online Sept. 16, 2013;
doi:10.1073/pnas.1312938110
Contact: Lakshmi A. Devi, Icahn School of Medicine at Mount Sinai, New York, N.Y.
e-mail:
lakshmi.devi@mssm.edu